DOI: 10.3724/SP.J.1263.2012.06251

Journal of Geriatric Cardiology 2012/9:4 PP.344-348

Association of inflammation with atrial fibrillation in hyperthyroidism

Objectives The aim of this study was to evaluate the relationship between inflammation and development of atrial fibrillation (AF) in patients with hyperthyroidism. Methods A total of 65 patients with newly diagnosed hyperthyroidism, 35 of whom were in sinus rhythm and 30 of whom in AF. Thirty five age- and gender-matched patients in a control group were included in the study. Factors associated with the development of AF were evaluated by multivariate regression analysis. Results Factors associated with AF in multivariate analysis included high sensitivity C reactive protein (HsCRP) [odds ratio (OR): 11.19; 95% confidence interval (95% CI): 1.80–69.53; P = 0.003], free T4 (OR: 8.76; 95% CI: 2.09–36.7; P = 0.003), and left atrial diameter (OR: 1.25; 95% CI: 1.06–1.47; P = 0.008). Conclusions The results of the present study suggest that HsCRP, an indicator of inflammation, free T4 and left atrial diameter are associated with the development AF in patients with hyperthyroidism.

Key words:Atrial fibrillation,Hyperthyroidism,Inflammation

ReleaseDate:2014-07-21 16:32:10

1 Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, et al. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Research 2009; 2: 4.

2 Staffurt JS, Gibberd JS, Tang FS. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 1977; 2: 688-690.

3 Selcuk MT, Selcuk H, Maden O, et al. Relationship between inflammation and atrial fibrillation in patients with isolated rheumatic mitral stenosis. J Heart Valve Dis 2007; 16: 468-474.

4 Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.

5 Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.

6 Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.

7 Ucer E, Gungor B, Erdinler IC, et al. High sensitivity CRP levels predict atrial tachyarrhythmias in rheumatic mitral stenosis. Ann Noninvasive Electrocardiol 2008; 13: 31-38.

8 Chiu-Braga YY, Hayashi SY, Schafranski M, et al. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): High levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein. Int J Cardiol 2006; 109: 275-276.

9 Golbasi Z, Ucar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease evidence of ongoing inflammation. Eur J Heart Fail 2002; 4: 593-595.

10 Yetkin E, Erbay AR, Ileri M, et al. Levels of circulating adhesion molecules in rheumatic mitral stenosis. Am J Cardiol 2001; 88: 1209-1211.

11 Ozaydin M, Turker Y, Erdogan D, et al. The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int J Cardiol 2010; 141: 147-150.

12 Ortmann C, Pfeiffer H, Du Chesne A, et al. Inflammation of the cardiac conduction system in a case of hyperthyroidism. Int J Legal Med 1999;112: 271-274.

13 Pearce EN, Bogazzi F, Martino E, et al. The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. Thyroid 2003; 13: 643-648.

14 Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: Cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003; 166: 379-386.

15 Senturk T, Kozaci LD, Kok F, et al. Proinflammatory cytokine levels in hyperthyroidism. Clin Invest Med 2003; 26: 58-63.

16 Siddiqi A, Monson JP, Wood DF, et al. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999; 84: 435-439.

17 Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.

18 Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007; 167: 928-934.

19 Heeringa J, Hoogendoorn EH, van der Deure WM, et al. High-normal thyroid function and risk of atrial fibrillation: The rotterdam study. Arch Intern Med 2008; 168: 2219-2224.

20 Iwasaki T, Naka M, Hiramatsu K, et al. Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves’ disease. Cardiology 1989; 76: 10-17.

21 Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-1252.

22 Wang J, Liu L, Feng J, et al. Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol 1996; 271: H148-H158.

23 Olsson SB. Atrial fibrillation-where do we stand today? J Intern Med 2001; 250: 19-28.

24 Chen YC, Chen SA, ChenYJ, et al. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol 2002; 39: 366-372.

25 Sun ZQ, Ojamaa K, Nakamura TY, et al. Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. J Mol Cell Cardiol 2001; 33: 811-824.

26 Wustmann K, Kucera JP, Zanchi A, et al. Activation of Electrical Triggers of Atrial Fibrillation in Hyperthyroidism. J Clin Endocrinol Metab 2008; 93: 2104-2108.

27 Biondi B, Fazio S, Coltorti F, et al. Clinical case seminar: Reentrant atrioventricular nodal tachycardia induced by levothyroxine. J Clin Endocrinol Metab 1998; 83: 2643-2645.

28 Tribulova N, Varon D, Polak-Charon S, et al. Aged heart as a model for prolonged atrial fibrilloflutter. Exp Clin Cardiol 1999; 4: 64-72.

29 Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361-379.

30 Spach MS, Heidlage JF. The stochastic nature of cardiac propagation at a microscopic level. An electrical description of myocardial architecture and its application to conduction, Circ Res 1995; 76: 366-380.

31 Komiya N, Isomoto S, Nakao K, et al. Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism. Clin Endocrinol 2002; 56: 39-44.

32 Freedberg AS, Papp JG, Vaughan-Williams EM. The effect of altered thyroid state on atrial intracellular potentials. J Physiol 1970; 207: 357-369.

33 Fazio S, Palmieri EA, Lombardi G, et al. Effects of Thyroid Hormone on the Cardiovascular System. Recent Progr Horm Res 2004; 59: 31-50.

34 Sgarbi JA, Villaca FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003; 88: 1672-1677.